INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 August 2017
Net Assets |
£252m |
Net Assets per share |
672p |
Share price |
624p |
Total value of unquoted investments |
£21m |
Total number of portfolio companies |
92 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Gilead |
7.8 |
Celgene |
7.7 |
Regeneron |
6.5 |
Biogen |
5.9 |
Vertex |
4.5 |
Alexion |
4.0 |
Incyte |
3.3 |
Shire |
3.2 |
Biomarin |
3.0 |
Genmab |
3.0 |
|
----------- |
Total |
48.9 |
Geographical Allocation |
% NAV |
US & Canada |
85 |
Europe & UK |
15 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
92 |
Unquoted |
8 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
51 |
Mid Cap =USD1-10BN |
25 |
Small Cap <USD1BN |
24 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
33 |
Rare diseases |
14 |
CNS |
12 |
Infectious Diseases |
11 |
Ophthalmology |
8 |
Inflammation |
7 |
Metabolic |
5 |
Medtech |
2 |
Other |
8 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
26 SEPTEMBER 2017